International Journal of Sciences:
Basic and Applied Research
(IJSBAR)
ISSN 2307-4531
(Print & Online)
http://gssrr.org/index.php?journal=JournalOfBasicAndApplied
---------------------------------------------------------------------------------------------------------------------------
Phytochemical, Pharmacological and Toxicological
Aspects of Capparis erythrocarpos Isert.: A Review
Michael Odoi Kyenea*, Mary-Ann Archerb, Susana Oteng Mintahc, Peter Atta
Adjeid, Genevieve Yeboahe, Doris Kumadohg, Alfred Ampomah Appiahh
a,b,e,f
Department of Pharmaceutics and Quality Control, Centre for Plant Medicine Research, Mampong,
Ghana
c
Department of Microbiology, Centre for Plant Medicine Research, Mampong-Akuapem, Ghana
d
Department of Plant Development, Centre for Plant Medicine Research, Mampong-Akuapem, Ghana
g,h
Department of Production, Centre for Plant Medicine Research, Mampong-Akuapem, Ghana
h
Department of Phytochemistry, Centre for Plant Medicine Research, Mampong-Akuapem, Ghana
a
Email: maekeal2002@yahoo.com, bEmail: maryannarcher16@yahoo.com
c
Email: susanaotengdapaah@yahoo.com, dEmail: peterattaadjeijunior@yahoo.com
e
Email: genevievenyeboah@gmail.com, gEmail: selasie100@yahoo.com
h
Email: alfredampomahappiah@yahoo.com
Abstract
Capparis erythrocarpos is a shrub plant with a large natural distribution used in traditional medicines to cure
various illnesses. The study sought to review and compile all data available on this medicinally important plant,
which will help inform scientists and researchers the gap needed to be filled in studying the plant. The present
review summarizes information concerning the ethnopharmacology, morphology, phytochemistry, toxicology
and biological activities of C. erythrocarpos. Scientific databases such as NCBI/PubMed, Google scholar, Sci
finder, Science direct were searched for published article on the plant. The active phytochemicals; flavonoids,
alkaloids, terpenoids, phytosterols, glycosides, tannins, coumarins and saponins have been identified from
various parts of the plant. Pharmacological and biological studies on the plant have revealed its antimicrobial,
analgesic, anti-inflammatory, antipyretic, anti-diabetic and anti-dyslipidemia activities, with no reported toxic
effect.
-----------------------------------------------------------------------* Corresponding author.
196
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
It is recommended that future studies should focus on identification, separation, purification and quantification
of the most bioactive constituents of C. erythrocarpos due to the paucity of information in this area.
Keywords: Capparis erythrocarpos; flavonoids; alkaloids; anti-inflammatory; ethnopharmacology.
1. Introduction
The large diversity of medicinal plant species is a huge source of potentially active phytochemicals with novel
structures that can be harnessed. According to Newman and Cragg, out of a total of 1881 new approved drugs in
the last four decades, 929 originated from natural sources and fall into the class of biological molecules,
unaltered natural products, botanical drugs, or derivatives of natural products, while the remaining 952 drugs are
classified as synthetic drugs or synthetic drugs with natural product pharmacophores[1]. As such, the
importance of medicinal plants cannot be over emphasized.
Capparis erythrocarpos Isert. is an important medicinal plant with known potent ethno-pharmacological
properties, and can be very useful in modern drug discovery. Plants of genus Capparis are trees or shrubs with
stipular thorns [2], comprising of about 700 species, of which only five have been identified in Ghana [3, 4].
These species are Capparis seperia L., Capparis brassii, Capparis fascicularis, Capparis tomentosa, and
Capparis erythrocarpos Isert [5,6]. C. erythrocarpos, is commonly used locally for the management of pain,
inflammation, chronic diarrhoea and other several ailments in Ghana and sub-Saharan Africa [7]. Based on its
traditional use a number of researches have been carried out to scientifically prove its anti-inflammatory [8],
analgesic [7,8], anti-nociceptive[9], anti-pyretic [10], anti-microbial [11,12], anti-diabetic [13] and antidyslipidaemic [14] activities. Some studies have also been conducted to identify the phytochemical constituents
that may be contributing to these reported activities. Even though there are a number of reported
pharmacological and biological activities of C. erythrocarpos, there is currently no review that puts together all
the data on the various reported activities. The present review seeks to compile all available data on the plant,
comprising its identification, ethno-pharmacological uses, secondary metabolites, pharmacological activities and
toxicological assessment. Although, there are not many published works involving this plant, which is the main
limitation of this study, the available literature was utilized for this work. The review will also help reveal
research areas which need to be investigated on the plant, as well draw scientific focus for strategic planning to
optimize its sustainable use.
2. Traditional uses
Ayurveda mention of this plant reveals the use of the stem bark and root for its analgesic and inflammatory
diseases [15]. The roots are used across Africa for the treatment of headache, conjunctivitis and chronic
diarrhoea [16,17]. Tropical Africans also use the leaves of the plant to treat child convulsive fever, pounded
roots are applied on severe abscess and vapour from the pounded roots are used to treat inflammation of the
connective tissue of the eye [18,19].
In Tanzania, the roots are used to treat skin rashes, tuberculosis, cryptococcal meningitis, oral candidiasis,
herpes zoster, herpes simplex and chronic diarrhoea [17].
197
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
The whole plant is used in Uganda for the management of menstrual pains, infertility and anemia [20]. In
Ethiopia, C. erythrocarpos is used traditionally for the management of symptoms of cyst and skin infections.
Kenyans also use the plant as an anti-diarrhoea and anthelmintic agent [7]. In Ghana, it is used as an
aphrodisiac, for the management of pain, arthritis and other forms of inflammatory conditions [21]. Various
parts of the plant have been processed into different dosage forms as commercial products on the Ghanaian
market (Table 1). Table 2 contains the various vernacular names by which the plant is referred to in different
localities.
Table 1: Commercial products on the Ghanaian market containing C. erythrocarpos
Product name
Manufacturer
Sirrapac [22]
Center
for
plant
Dosage form
Type
Indication
Powder
Monoherbal
Treatment
medicine research
of
rheumatoid
arthritis
Alomo bitters [23]
Kasapreko Ltd.
Tincture
Polyherbal
Appetizer
Class bitters [24]
Class herbal Centre
Decoction
Polyherbal
Backache, general body pains
and sexual weakness
Ltd: Limited
Table 2: Vernacular names of C. erythrocarpos
Country
Tribe
Vernacular name
Ghana
Ewe
Lalenui, Anngo
[21]
Ghana
Ashante
Woresenakyiame
[21]
Ghana
Fante
Okyerubrcm
[21]
Ghana
Ga
Aqmaqma
[21]
Uganda
Muzingani omwelu
[25]
Uganda
Kitunku ekitono
[25]
Tanzania
Oluvuranganga
[17]
198
Reference
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
3. Plant description
C. erythrocarpos which emerges from the kingdom Plantae, also falls under the clade Tracheophytes. It is an
Angiosperm, Eudicot and Rosid. It is found among the members of the order Brassicales, in the family
Capparaceae, commonly known as the caper family, genus Capparis and species erythrocarpos [21,26,27].
C. erythrocarpos is usually described as a scandent shrub or climber, armed with sharp, paired hooked thorns
(Figure 1). Branches slightly zigzag, greyish-velvety when young. The stem of the plant can be described as
weak, light green when young and brown when old. The leaves are fleshy with a glossy appearance. The striking
difference between the young and old leaves is the light green lanceolate shaped young leaves as opposed to
dark green elliptical to ovate old leaves [28]. The leaf base is cuneate to rounded. The apex is sharply acuminate
to obtuse with dimensions of 3-14 cm long and 1.5-5 cm broad. Its flowers or stout pedicels (2-2.5 cm long) are
clustered at the end of a leafy shoot, petals are mostly emarginated, ovary ribbed and the fruit scarlet is 5 cm
long [21]. The flowers are solitary, axillary, white in colour but often pink at the base of the stamens. Iner sepals
are petaloid greenish white, 3-4 times longer than outer sepals [29]. Stamens 40-50, up to 2.8 mm long [29].
Fruits ellipsoid, 4 × 2.5 cm, strongly 6-8 ridged and deep-pink when ripe (Figure 2) [29]. Seeds are brown in
colour and usually 15-20 per fruit.
Figure 1: Pictures of root, root bark and full plant of C. erythrocarpos. Source: CPMR arboretum MampongAkuapem, Ghana.
199
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
Figure 2: Pictures of Seeds, seedlings, inflorescence and ripe fruits of Capparis erythrocarpos. Source: CPMR
arboretum, Mampong-Akuapem, Ghana.
4. Pharmacognostic Characterization of Capparis erythrocarpos
4.1 Leaf
The fresh matured leaves are green in color, elliptical to ovate shaped, bitter to taste and musty in odor. The
leaves are alternately arranged with pinnate venation, sinuate margin, acute apex, short stalked petiole with two
spiny stipules on its symmetrical base [30]. C. erythrocarpos has small amphistomatic leaves 18-19 which
shorten travel distance of carbon dioxide to the mesophyll cells in the leaves [31]. This feature enhances
photosynthesis in C. erythrocarpos [32,33]. Thick outer epidermal walls, a feature of xerophytes which was
confirmed in C. erythrocarpos [34,30]. These observed features are essential for easy identification and
authentication of the plant. Safranin, a stain for detecting different types of cells; lignified, cutinized or
suberized cell wall confirmed the presence of lignin and suberin in C. erythrocarpos leaves [30]. For leaf
surface determination, the stomata of C. erythrocarpos is shorter (0.018 ± 0.004 mm) but broader (0.019 ± 0.003
mm) than other member of the genus [30]. Another distinctive feature about C. erythrocarpos leaves is its
hyperstomata. Anomocytic stomata is the main type of stomata present on both surfaces of the leaf. Other types
of stomata present include anisocytic and actinocytic [30].
200
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
4.2 Stem
Twumasi and her colleagues also reported on the morphological features of the stem of C. erythrocarpos. The
young stems are green, matured stems are greenish brown and the inner parts are creamish white. The stem
showed white patches, lenticels and wrinkles which are well distributed all over the outer bark [28]. C.
erythrocarpos stem possesses thorns [3,34]. It also has thick fibre vessels arranged within the collateral vascular
bundle and small, compact parenchymatous cells. C. erythrocarpos has cortical sclereids but not pericyclic
fibres. A transverse section of the stem of the plant reveals a lot of branched and stellate trichomes attached to a
thick layer of cuticle. There is only a single layer of epidermal, isodiametric parenchyma cells and a pith
containing prismatic calcium oxalate crystals with numerous starch grains. The vascular bundle has lignified
vessels with outer phloem. The powdered stem contains a lot of starch grains, numerous vessels and lignified
sclerenchymatous cells [28,35].
4.3 Root
The root of C. erythrocarpos has a bitter taste with macromorphological features of the root similar to the stem.
The root has one to two layer(s) of epidermal cells overlaid with a cork with no trichome and four to seven
layers of cortical collenchyma cells. Highly dispersed through the isodiametric parenchyma cells are large starch
grains and stone cells. Present is a collateral vascular bundle and lignified medullary rays consisting of 15-25
rows of parenchyma. In the middle lies a pith. All throughout the cells in the section (from the epidermis to the
pith) are oil deposits. The powdered root showed similar structures as the stem but it lacked trichomes and had
smaller secretory cell [28].
5. Ecology
The plant thrives in the thickets of coastal scrub and islands. The plant can be found in Congo, Angola, Sudan,
Uganda, Ghana and East Africa. In Ghana, it can be found in and around Tema of the Greater Accra region and
on the Accra plains in the Eastern Region [21]. C. erythrocarpos survives in a wide range of climatic conditions
but seem to prefer dry humid semi-savannah regions. It also has savannah adaptive features such as deep tap
root that enable it to survive in its habitat and drought periods.
6. Phytochemical screening
Qualitative and quantitative analysis of phytochemicals of a particular plant defines its biological, nutritional,
and pharmaceutical attributes. Hence investigating the profile of biochemicals and bioactives in a medicinal
plant is considered as a vital parameter to exploring its nutraceutical and or pharmaceutical applications [36].
Unfortunately, there is no literature record of any quantitative phytochemical evaluation and active compounds
isolated from the C. erythrocarpos.
In a qualitative phytochemical analysis, Danquah and his colleagues (2011) reported the presence of flavonoids
and alkaloids as the predominant chemical constituents in the ethanolic root extract of C. erythrocarpos [10].
Similarly, Woode and his colleagues (2009) also reported the presence of high amount of alkaloid, and
201
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
flavonoid with traces of triterpenes in the crude ethanolic root extract [9]. A more recent study revealed that,
the root bark of the plant contains the highest number (five) of phytochemical constituents whiles the stem and
the leaf contains equal numbers (four each). Reducing sugar, triterpenes and phytosterols were presents in all the
three extracts. In addition, saponins were present in the root bark and leaf but absent in the stem. Alkaloids were
also present in the root bark and stem extracts but not in the leaf [8].
Twumasi and her colleagues also investigated the phytochemical constituents in an aqueous extract of C.
erythrocarpos. Saponins, tannins, glycosides, flavanols, triterpenoids, coumarins and alkaloids were detected in
the powdered leaves, stem and roots of the plant [37]. All the above researchers employed standard techniques
such as Mayer’s tests for alkaloids, Fehling’s test for reducing sugars, Liebermann-Burchard’s test for
phytosterol and triterpeness, froth test for saponins, Shinoda’s test for flavonoids, Borntrager’s test for free
anthraquinones and Ferric chloride solution test for phenolics for the phytochemical analysis.
7. Biological/ Pharmacological activity
C. erythrocarpos has been reported to exhibit a number of pharmacological and biological activities, which have
been discussed below and summarized in Table 3.
7.1
Anti-inflammatory (anti-arthritic) and Analgesic activity
C. erythocarpos is widely known for its anti-inflammatory and pain-relieving properties. Infections, physical
and chemical agents can stimulate acute inflammatory response, which when unresolved lead to chronic
inflammation that can cause major threat to human health and lead to development of various diseases.
Carrageenan is commonly used to induce acute inflammation, characterized by oedema, which serves as a
model for assessing the acute anti-inflammatory property of medicinal agents. Various studies on different parts
of the plant have been carried out and reported to confirm the anti-inflammatory, anti-nociceptive and analgesic
activity of the plant. A study by Danquah and his colleagues (2011), to assess the acute anti-inflammatory
activity of C. erythrocarpos revealed that, the ethanolic root extract (10-300 mg/kg) administered before
inducing carrageenan foot oedema in chicks, significantly reduced induced foot oedema with maximal inhibition
of 48.86±20.41% and ED50 value of 59.37±18.83 mg/kg. Kumatia and his colleagues (2019), further proved the
acute anti-inflammatory and analgesic activities of C. erythrocarpos, by comparing the stem and leaf to the root
bark, in order to get a substitute for the commonly used root bark which is making the plant go on extinction,
using the carrageenan induced paw oedema, hot plate and acetic acid induced writhing assays. The root bark and
leaf extracts at 200 mg/kg p.o. significantly (p<0.05) exhibited anti-inflammatory activity of 48.93% and
37.42% respectively. The extracts again produced significant (p<0.05) analgesic activity (178.20 – 248.70 %)
which was higher than morphine (136.70%) at 5 mg/kg in the hot plate assay. The stem extracts (200 mg/kg)
showed the highest analgesic activity of 54.61% in the writhing assay [38].
202
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
Table 3: Summary of the Pharmacological activities of C. erythrocarpos
Pharmacological
activity
Plant part
Type of extract
Dose range
(mg/kg)
Experimental model / method
ED50
(mg/kg)
10 – 300
Minimal
active dose
(mg/kg)
10
Anti-inflammatory
Root
Ethanol
Root bark
Leaves
Carrageenan foot oedema
59.37
18.83
Hydro-ethanol
Hydro-ethanol
5 – 200
5 – 200
5
5
Carrageenan induced paw oedema test
Carrageenan induced paw oedema
[8]
Stem
Leaves
Root bark
Hydro-ethanol
5 – 200
5
Hot plate Assay and
Acetic acid induced writhing assays
[8]
Stem
Leaves
Root
Aqueous
30 – 300
30
Von-Frey filament of bending force of 9 g
[37]
Ethanol
30 – 300
30
Freund’s adjuvant arthritis model
35.59
15.73
Aqueous
30 – 300
30
Freund’s adjuvant arthritis model
Hydro-ethanol
10 – 300
181.5
182.5
36.4
Anti-nociceptive
Root
Stem
Leaves
Stem
leaves
Root
Root
10
Formalin-induced nociceptive test
[9]
Anti-pyretic
Root
Hydro-ethanol
30 – 300
30
Baker’s yeast induced pyrexia
[10]
Anti-dyslipidaemia
Root back
Hydro-ethanol
20 – 200
20
[14]
Anti-diabetic
root
Hydro-ethanol
100 – 1000
100
Atherogenic indices assay
Blood pressure determination
Streptozotocin-induces diabetes
Oral glucose tolerance test
Analgesic
Anti-arthritic
203
Reference
±
±
[10]
[38]
[37]
[13]
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
The analgesic activity of the extracts may be due to their ability to suppress the cyclooxygenase enzyme and
decrease the biosynthesis of prostaglandins, and as a result of the presence of secondary active metabolites.
These metabolites act by eradicating inflammatory pain mediators and block the experience of pain [39,40].
These secondary metabolites also prevent mitochondrial leakage, free radical outflow, damage of the
mitochondrion and pain associated with oxidative stress which occurs as a result of mitochondrial redox reaction
[41,42,43].
A model for chronic inflammation, adjuvant-induced arthritis in rats, which mimics rheumatoid arthritis in
humans, was employed by Danquah and his colleagues (2011) to provide scientific confirmation for the use of
the plant locally as an anti-arthritic agent. Complete Freund’s Adjuvant (CFA) was injected into the right paw of
rats to induce arthritis which was measured using water displacement plethysmography. It was reported that the
ethanolic root extract (30 mg kg-1; p.o.) administered in therapeutic treatment, significantly (F 3,16 = 4.25, p =
0.02) reduced adjuvant-induced arthritis with maximal inhibitions of 34.19±15.73% and also significantly (F
3,16 = 4.28, p = 0.02) prevented the spread of arthritis from the ipsilateral to the contralateral paw [10].
However, higher doses of the extract (100 and 300 mg kg-1; p.o.) had no significant inhibition on the induced
arthritis. Twumasi and his colleagues (2019), compared the anti-arthritic and analgesic effects of three different
parts (leaves, stem and root) of C. erythrocarpos, employing the complete Freund's adjuvant arthritis model and
measuring responses to Von Frey filament number 9, respectively [37]. Also, the mechanism of antiinflammation was determined. It was reported that extracts from all the parts, leaves, stem and root reduced paw
volumes significantly, with ED50 values of 182.5, 181.5 and 36.4 mg kg-1 respectively. Results obtained for the
roots were in agreement with findings from previous studies where the least dose was the most active against
inflammation [8,10]. The higher doses of all extracts gave a lower potency and this could have resulted from the
presence of other secondary metabolites in the extract that mask the anti-inflammatory activity when they are
present in sizable quantities. The leaf extract (100 mg kg-1) showed analgesic activity with a decrease in
percentage response to Von Frey filament 9. Lower doses of all extracts reduced Tumor Necrosis Factor-alpha
(TNF-α) levels, with that of stem extracts reducing Interleukin-6 (IL-6). The extracts also reversed elevated
White blood cells (WBC) and platelets levels. The observed anti-arthritic activity of the leaf, stem and root bark
may be due to the inhibition of the release of inflammatory mediators at the various phases of arthritis.
In a mouse formalin test, Woode and his colleagues (2009) assessed the antinociceptive effect of ethanol root
extract, the extract (10-300 mg kg-1) dose dependently reduced pain scores in both phases of the formalininduced nociception, indicating both central and peripheral effects. Morphine (1- 10 mg kg-I; i.p.) was used as
positive control. Morphine, an opioid agonist was antinociceptive and inhibited both phases of the formalin
response which clearly depicts that it is a centrally acting analgesic drug. At dose 100 mg kg-1, the formalininduced pain was significantly reduced in the first and second phases of nociception by 47.54±5.65 and
80.01±3.77%, respectively by the extract. The analgesic effect was further investigated to determine the possible
mode of action(s) of the extract by using the non-selective opioid receptor antagonist naloxone and nonselective adenosine receptor antagonist theophylline. The results showed that, naloxone reversed the effect of
morphine as expected but naloxone however, did not reverse the antinociceptive effect of the extract in both
phases, suggesting that opioid receptor activation was not involved in the antinociceptive effect of the extract.
The antinociceptive effect of the plant was completely reversed in the first phase and significantly reversed in
204
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
the second phase by theophylline, which suggest that, adenosine is involve in the antinociceptive effect of C.
erythrocarpos [9].
7.2 Antipyretic activity
Pyrexia is a sign associated with a number of diseases including infections and inflammatory conditions. Yeast
induced fever is an efficient and consistent technique employed to investigate and search for new antipyretic
drugs [44]. A study by Danquah and his colleagues (2011a) to assess the antipyretic activity of the plant’s
ethanol root extract (30-300 mg kg-1) employed the baker’s-yeast induced pyrexia in rats. The antipyretic
activity of the extract showed that C. erythrocarpos caused a significant reduction in rectal temperature however,
the effect was not as pronounced and sustained as compared to the standard used (paracetamol). The authors
concluded that, the results support the view that the extract has some influence on Protaglandin-biosynthesis,
since prostaglandin is believed to be a regulator of body temperature. The extract produced a significant and
dose-dependent (F 4, 15 = 51.85, P<0.0001) reduction in the rectal temperature whiles paracetamol (10-100 mg
kg-1) caused a reduction in rectal temperature of the rats in a dose dependent manner (F 4, 15 = 78.87,
P<0.0001). The antipyretic effect began from the first hour after the drug administration and was sustained for 4
hours [10].
7.3 Anti-dyslipidaemic Activity
The anti-dyslipidaemia effect of Sirrapac, a milled root bark of C. erythrocarpos, investigated in male adult
Sprague-Dawley rats over a three-month period, assessed the rats’ body weight, food intake, Serum triglycerides
(TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDLC), low density lipoprotein-cholesterol
(LDLC), leptin levels and effect on blood pressure [14].
The hydro-ethanol extract of Sirrapac (20, 100 and 200 mg kg-1), dose dependently and significantly (p < 0.05)
reduced body weight, food intake, serum levels of TC, LDLC, TG and serum leptin with significant (p < 0.05)
increase in levels of HDLC. There was also a significant decrease in rat systolic blood pressure with no effect on
the diastolic blood pressure, indicating its anti-lipidaemic effects and ability to manage cardiovascular diseases
and other associated problems, like obesity [14]. The reduction in body weight may be due to loss of appetite in
the animals. The milled root bark directly acts to reduce appetite and fats circulation, which prevents the
deposition of fats as energy stores in the adipose tissues.
7.4 Anti-diabetic activity
Diabetes mellitus which is a chronic endocrine and metabolic condition results when the pancreatic beta-cells
are not able to maintain sufficient secretion of insulin or when the cells of the body are unable to fully utilize the
produced insulin. It is associated with persistent hyperglycemia and dyslipidemia which can lead to
cardiovascular diseases and other metabolic conditions. The anti-dyslipidaemic activity of C. erythrocarpos
therefore makes it a potential anti-diabetic agent.
The in-vivo anti-diabetic activity was investigated by Nyondo and his colleagues (2020), employing the
205
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
streptozotocin (STZ)-induced diabetes in mice. Also, the oral glucose tolerance test (OGTT) was employed to
investigate the acute anti-hyperglycemic activity in normal mice. The hydro-ethanolic root extract of C.
erythrocarpos after 14 days of daily oral administration in STZ-induced diabetic mice, significantly at doses 250
mg kg-1 (p = 0.0267), 500 mg/kg (p = 0.0002) and 1000 mg kg-1 (p = 0.0011), reduced the level of fasting
blood glucose. After 2 hours of oral glucose load in OGTT, the extract significantly lowered the blood glucose
levels at doses of 100 mg kg-1 (p = 0.0322), 200 mg kg-1 (p = 0.0118) and 500 mg/kg (p = 0.0222) [13].
Diabetes mellitus which is a chronic endocrine and metabolic condition results when the pancreatic beta-cells
are not able to maintain sufficient secretion of insulin or when the cells of the body are unable to fully utilize the
produced insulin. It is associated with persistent hyperglycemia and dyslipidemia which can lead to
cardiovascular diseases and other metabolic conditions [45]. The anti-dyslipidaemic activity of C. erythrocarpos
may therefore contribute to its anti-diabetic potential.
8. Antimicrobial activity
Antibacterial and anti-fungal activity of C. erythrocarpos leaf extracted successively with ether and methanol
was tested against Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922), Pseudomonas
aeruginosa (ATCC 27853) and Candida albicans (clinical isolates) using the agar well diffusion and the broth
serial dilution assays. The ether leaf extract exhibited activity against all the test microorganisms with mean
zones of inhibition of 26.3±2.03mm (C. albicans), 26.3±0.58mm (S. aureus), 25.3±1.53mm (E. coli) and
13.0±0.00mm (P. aeruginosa), the methanol extract had no activity against E. coli and P. aeruginosa. However,
E. coli was most susceptible to the ether extract with the least MIC of 320µg mL-1, followed by C. albicans, S.
aureus and P. aeruginosa with MICs of 330, 400 and 500 µg mL-1, respectively. The methanol extract showed
activity against C. albicans and S. aureus with MIC of 500 and 530 µg mL-1, respectively [11]. The anti-fungal
efficacy testing of the dichloromethane root extract was also assessed in-vivo using the mice infection model.
Immunocompromised mice were infected with 0.3 mL of 0.5 McFarland standard inoculum of C. albicans and
then treated with 100, 200 and 400 mg kg-1 of the extract. The extract dose dependently reduced the fungal load
with respective mice survival. The extract at the test doses showed significant anti-fungal activity with organ
burden clearance ranging from 64.0%–99.9% (P < 0.0001). The highest dose (400 mg kg-1) of the root extract
was the most effective with mice survival of 60% [12].
9. Toxicological assessment
The first reported acute and sub chronic toxicity study was by Woode and his colleagues (2009). The
researchers administered high doses of ethanolic extract (300-3000 mg kg-1 p.o) to mice, followed by close
monitoring for signs of toxicity for 24 hours and 14 days, respectively. The results showed no remarkable signs
of toxicity either immediately or during the post – treatment period even at the highest dose of 3000 mg kg-1 of
body weight. Also, there were no changes in behavior, activity, posture, or external appearance that were
considered to be test drug related. All the animals also survived throughout the 24 hours and the 14 days study
period, respectively. There were generally no statistically significant changes in the hematological indices and
biochemical parameters taken, suggesting that the extract has a high safety profile [9].
Martey and his
colleagues (2013) also researched on the safety of the root bark of C. erythrocarpos, in male Sprague-Dawley
206
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
rats by evaluating the effects of C. erythrocarpos on the function and/or morphology of key organs such as the
liver, kidney, lung, heart and the bone marrow. After 6 months of chronic administration of C. erythrocarpos at
18 and 180 mg kg-1 body weight to the rats, the effects of the plant on certain serum biochemical,
haematological, urine and histopathological determinations were used as indices of organ specific toxicity. The
results indicated that C. erythrocarpos had no effect on urine, hematological and serum biochemical indices at
termination of treatment with the exception of serum ALT level which was significantly (p<0.05) attenuated in a
dose-dependent fashion (21-35%), an indication that the plant extract or its metabolite(s) inhibits ALT activity.
This therefore, indicates that these organs were not adversely affected by C. erythrocarpos treatment.
Histopathological studies showed that C. erythrocarpos did not adversely affect the morphology of the liver,
kidney and heart tissues. However, lungs of the animals showed slight but insignificant inflammatory response
in alveolar areas and Clara cell hyperplasia without the thickening of alveolar septa and bronchiolar epithelial
wall. C. erythrocarpos did not affect any of the hematological indices which suggests that it did not suppress or
damage the bone marrow or directly affected the blood cells. The lack of effect of the plant extract on blood
clotting time suggested that it does not affect vitamin K levels or inhibit the synthesis of blood clotting proteins.
The latter is supported by the fact that serum albumin levels were not affected by C. erythrocarpos treatment,
suggesting that hepatic protein biosynthetic activity was not impaired. However, there were significant (p<0.05)
changes in weight of C. erythrocarpos-treated animals with duration of treatment compared to control [22]. This
phenomenon was later investigated by Saka and his colleagues and the authors concluded that, the reduction of
body weight of the test animals may be through the suppression of appetite with subsequent reduction in fat
uptake and deposition [14]. These results suggest that there is no organ specific toxicity associated with chronic
administration of C. erythrocarpos in rats.
10. Conclusion and Recommendation
From the review of the existing works, it may be concluded that C. erythrocarpos has been used in the treatment
of various diseases and reported to have anti-inflammatory, analgesic, anti-dyslipidaemic, anti-diabetic,
antipyretic and antimicrobial activities. Despite the many pharmacological activities shown by this plant, some
other activities like aphrodisiac and use of the plant for treatment of chronic diarrhoea which are traditionally
known has not yet been confirmed through research yet.
Finally, we recommend that future studies should focus on identification, separation, purification and
quantification of the most bioactive constituents of C. erythrocarpos. Pharmacological evaluation of its
aphrodisiac and anti-diarrhoea activities must be studied. The effective dose must also be ascertained for future
clinical trials on the pharmacological action of C. erythrocarpos.
11. Conflict of Interest
Authors declare that there are no conflicts of interest
References
[1] D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the nearly four
207
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
decades from 01/1981 to 09/2019,” J. Nat. Prod., vol. 83, no. 3, pp. 770–803, 2020.
[2] J. Hutchinson, The genera of flowering plants (Angiospermae) Vol-2. Oxford Univeristy Press;
London, 1967.
[3] F. R. Irvine, “Woody plants of Ghana.,” Oxford University Press: Oxford, pp. 653, 1961.
[4] U. Quattrocchi, CRC world dictionary of medicinal and poisonous plants: common names, scientific
names, eponyms, synonyms, and etymology (5 Volume Set). CRC press, 2012.
[5] J. Jenik and J. B. Hall, “Plant communities of the Accra plains, Ghana,” Folia Geobot. Phytotaxon.,
vol. 11, no. 2, pp. 163–212, 1976.
[6] M. D. Swaine, “Characteristics of dry forest in West Africa and the influence of fire,” J. Veg. Sci., vol.
3, no. 3, pp. 365–374, 1992, doi: 10.2307/3235762.
[7] M. A. Twumasi et al., “Leaves and stems of Capparis erythrocarpos, more sustainable than roots, show
antiarthritic
effects,”
J.
Ethnopharmacol.,
vol.
238,
no.
April,
p.
111890,
2019,
doi:
10.1016/j.jep.2019.111890.
[8] E. K. Kumatia, S. Antwi, H. Brew-Daniels, A. A. Appiah, and A. Ocloo, “In vivo Comparative AntiInflammatory and Analgesic Activities of Root Bark, Stem and Leaf Extracts of Capparis
erythrocarpus (Capparaceae),” Pharmacogn. J., vol. 11, no. 3, pp. 515–520, 2019, doi:
10.5530/pj.2019.11.82.
[9] E. Woode, C. A. Danquah, E. Boakye-Gyasi, C. Ansah, G. Ainooson, and E. Woode, “Antinociceptive
effects of an ethanolic extract of Capparis erythrocarpos isert roots in the mice formalin test,” Int. J.
Pharmacol., vol. 5, no. 6, pp. 354–361, 2009, doi: 10.3923/ijp.2009.354.361.
[10] A. Danquah, E. Woode, B. Gyasi, M. Duwiejua, and C. Ansah, “Anti-inflammatory and antipyretic
effects of an ethanolic extract of capparis erythrocarpos isert roots,” Res. J. Med. Plant, vol. 5, no. 2,
pp. 158–168, 2011, doi: 10.3923/rjmp.2011.158.168.
[11] G. Anywar, “Antibacterial and Antifungal Properties of Some Wild Nutraceutical Plant Species from
Nebbi District, Uganda,” Br. J. Pharm. Res., vol. 4, no. 14, pp. 1753–1761, 2014, doi:
10.9734/bjpr/2014/11443.
[12] D. P. Kisangau, K. M. Hosea, H. V. M. Lyaruu, C. C. Josep, Z. H. Mbwambo, and P. J. Masimba, “In
vivo Anticandida Activity of Three Traditionally Used Medicinal Plants in East Africa,” vol. 3, pp.
357–373, 2017, doi: 10.1007/978-94-024-1120-1_14.
[13] G. Nyondo et al., “In-vivo anti-diabetic activity of Capparis erythrocarpos (Capparaceae) root extract,”
Am. J. Physiol. Biochem. Pharmacol., vol. 10, no. 2, p. 48, 2020, doi: 10.5455/ajpbp.20191004054714.
208
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
[14] P. Saka et al., “The anti-dyslipidemic effects of milled root bark ethanolic extract of Capparis erythro
carpus in Sprague-Dawley rats: Implications for obesity and cardiovascular diseases,” J. Appl. Pharm.
Sci., vol. 8, no. 1, pp. 001–008, 2018, doi: 10.7324/JAPS.2018.8101.
[15] A. B. Kakooko and S. A. Kerwagi, “Medicinal plants in Uganda.,” 1996.
[16] P. W. Geissler et al., “Medicinal plants used by Luo mothers and children in Bondo district, Kenya,” J.
Ethnopharmacol., vol. 83, no. 1–2, pp. 39–54, 2002, doi: 10.1016/S0378-8741(02)00191-5.
[17] D. P. Kisangau, H. V. M. Lyaruu, K. M. Hosea, and C. C. Joseph, “Use of traditional medicines in the
management of HIV/AIDS opportunistic infections in Tanzania: A case in the Bukoba rural district,” J.
Ethnobiol. Ethnomed., vol. 3, pp. 1–8, 2007, doi: 10.1186/1746-4269-3-29.
[18] F. Haerdi, “The Indigenous Medicinal Plants of Ulanga District, Tanzania, East Africa.,” Acta Trop.,
no. Suppl. 8, pp. 1–278, 1964.
[19] I. Hedberg, O. Hedberg, P. J. Madati, K. E. Mshigeni, E. N. Mshiu, and G. Samuelsson, “Inventory of
plants used in traditional medicine in Tanzania. I. Plants of the families Acanthaceae-Cucurbitaceae,” J.
Ethnopharmacol., vol. 6, no. 1, pp. 29–60, 1982.
[20] A. Baldascini, “Income generating opportunities arising from natural ecosystems in Uganda,” Int. Food
Policy Res. Institute, Washingt. DC, USA, 2002.
[21] N. R. Mshana et al., “Traditional medicine and pharmacopoeia,” Contrib. to Revis. Ethnobot. Florist.
Stud. Ghana. Organ. African Unity/Scientific, Tech. Res. Commision, Accra, 2000.
[22] O. N. Martey, G. E. Armah, A. A. Sittie, and L. K. Okine, “A chronic toxicity study of the ground root
bark of Capparis erythrocarpus (Cappareceae) in male Sprague-Dawley rats.,” Pak. J. Biol. Sci., vol.
16, no. 23, pp. 1706–1713, 2013.
[23] O. S. Adeyemi and M. C. Owoseni, “Polyphenolic content and biochemical evaluation of fijk, alomo,
osomo and oroki herbal mixtures in vitro,” Beni-Suef Univ. J. Basic Appl. Sci., vol. 4, no. 3, pp. 200–
206, 2015, doi: 10.1016/j.bjbas.2015.07.002.
[24] K. C. Patrick-Iwuanyanwu and K. W. Nkpaa, “Toxicity effect of sub-chronic oral administration of
class bitters® - a polyherbal formula on serum electrolytes and hematological indices in male Wistar
albino rats,” J. Xenobiotics, vol. 5, no. 1, pp. 5–8, 2015, doi: 10.4081/xeno.2015.5369.
[25] J. R. S. Tabuti, C. B. Kukunda, and P. J. Waako, “Medicinal plants used by traditional medicine
practitioners in the treatment of tuberculosis and related ailments in Uganda,” J. Ethnopharmacol., vol.
127, no. 1, pp. 130–136, 2010.
[26]
POWO. "Plants of the World Online. Facilitated by the Royal Botanic Gardens, Kew. Internet:
209
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
www.plantsoftheworldonline.org/?q=Capparis+erythrocarpos [Jun. 12, 2021].
[27] Capparis erythrocarpos Isert in GBIF Secretariat, GBIF Backbone Taxonomy, 2019. internet:
www.GBIF.org, [Apr. 01, 2021].
[28] M. Twumasi, E. Ekuadzi, M. K, M. Boakye-Gyasi, M. LK, and E. Woode, “Pharmacognostic Studies
of the Leaves, Stem and Root of Capparis erythrocarpos Isert (Capparaceae),” Pharmacogn. J., vol. 11,
pp. 112–118, Jan. 2019, doi: 10.5530/pj.2019.1.19.
[29] M. A. Hyde, B. T. Wursten, and P. Ballings, “Flora of Zimbabwe.,” Flora of Zimbabwe., 2020. Species
information:
Capparis
erythrocarpos
var.
https://www.zimbabweflora.co.zw/speciesdata/species.php?species_id=124430,
rosea.
retrieved
[Dec. 02, 2020].
[30] T. A. Mary, E. Edmund, M. K. Priscilla, B. G. E. Mariam, M. L. K. Merlin, and W. Eric,
“Pharmacognostic studies of the leaves, stem and root of capparis erythrocarpos isert (Capparaceae),”
Pharmacogn. J., vol. 11, no. 1, pp. 112–118, 2019, doi: 10.5530/pj.2019.1.19.
[31] D. F. Parkhurst, S. Wong, G. D. Farquhar, and I. A. N. R. Cowan, “Intercellular CO2,” Plant Physiol.,
no. 1988, pp. 1032–1037, 1988.
[32] K. A. Mott, A. C. Gibson, and J. W. O’Leary, “The adaptive significance of amphistomatic leaves,”
Plant. Cell Environ., vol. 5, no. 6, pp. 455–460, 1982.
[33] H. J. Peat and A. H. Fitter, “A comparative study of the distribution and density of stomata in the
British flora,” Biol. J. Linn. Soc., vol. 52, no. 4, pp. 377–393, 1994.
[34] S. Rhizopoulou and G. K. Psaras, “Development and Structure of Drought‐tolerant Leaves of the
Mediterranean Shrub Capparis spinosa L.,” Ann. Bot., vol. 92, no. 3, pp. 377–383, 2003.
[35] R. Veerasamy et al., “Biosynthesis of silver nanoparticles using mangosteen leaf extract and evaluation
of their antimicrobial activities,” J. Saudi Chem. Soc., vol. 15, no. 2, pp. 113–120, 2011, doi:
10.1016/j.jscs.2010.06.004.
[36] T. Gull, F. Anwar, B. Sultana, M. A. C. Alcayde, and W. Nouman, “Capparis species: A potential
source of bioactives and high-value components: A review,” Ind. Crops Prod., vol. 67, pp. 81–96,
2015, doi: 10.1016/j.indcrop.2014.12.059.
[37] M. A. Twumasi et al., “Leaves and stems of Capparis erythrocarpos, more sustainable than roots, show
antiarthritic effects,” J. Ethnopharmacol., vol. 238, p. 111890, 2019, doi: 10.1016/j.jep.2019.111890.
[38] C. A. Danquah, E. Woode, and E. Boakye-Gyasi, “Anti-arthritic effects of an ethanolic extract of
capparis erythrocarpos isert roots in freund’s adjuvant-induced arthritis in rats,” J. Pharmacol. Toxicol.,
210
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2022) Volume 61, No 1, pp 196-211
vol. 6, no. 3, pp. 201–217, 2011, doi: 10.3923/jpt.2011.201.217.
[39] M. G. Nair et al., “Dietary food supplement containing natural cyclooxygenase inhibitors and methods
for inhibiting pain and inflammation.” Google Patents, Nov. 16, 2004.
[40] J. A. O. Ojewole, “Analgesic, antiinflammatory and hypoglycemic effects of Sutherlandia frutescens R.
BR.(variety Incana E. MEY.)(Fabaceae) shoot aqueous extract.,” Methods Find. Exp. Clin. Pharmacol.,
vol. 26, no. 6, pp. 409–416, 2004.
[41] C. H. Foyer and G. Noctor, “Redox sensing and signalling associated with reactive oxygen in
chloroplasts, peroxisomes and mitochondria,” Physiol. Plant., vol. 119, no. 3, pp. 355–364, 2003, doi:
10.1034/j.1399-3054.2003.00223.x.
[42] J. M. McCord, “The evolution of free radicals and oxidative stress,” Am. J. Med., vol. 108, no. 8, pp.
652–659, 2000, doi: 10.1016/S0002-9343(00)00412-5.
[43] N. Li et al., “Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing
mitochondrial reactive oxygen species production,” J. Biol. Chem., vol. 278, no. 10, pp. 8516–8525,
2003.
[44] J. Tomazetti et al., “Baker yeast-induced fever in young rats: Characterization and validation of an
animal model for antipyretics screening,” J. Neurosci. Methods, vol. 147, no. 1, pp. 29–35, 2005, doi:
10.1016/j.jneumeth.2005.03.002.
[45] K. G. M. M. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus
and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a
WHO consultation,” Diabet. Med., vol. 15, no. 7, pp. 539–553, 1998.
211